Sialic Acid Binding Immunoglobulin-like Lectins

A family of SIALIC ACID binding proteins found in vertebrate species. They are transmembrane proteins which act as cell surface receptors for a variety of sialylated GLYCOCONJUGATES. While a subset of siglec protein subtypes are evolutionarily conserved between mammalian species, there are many others that are species specific.

Also Known As:

Networked: 377 relevant articles (9 outcomes, 56 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Varki, Ajit: 21 articles (02/2021 - 05/2006)
2.	Crocker, Paul R: 15 articles (01/2021 - 02/2007)
3.	Bochner, Bruce S: 14 articles (07/2022 - 06/2011)
4.	Angata, Takashi: 12 articles (01/2022 - 05/2007)
5.	Läubli, Heinz: 11 articles (01/2022 - 09/2014)
6.	Nitschke, Lars: 11 articles (01/2021 - 01/2013)
7.	Paulson, James C: 10 articles (07/2022 - 05/2009)
8.	von Gunten, Stephan: 8 articles (12/2021 - 08/2011)
9.	Macauley, Matthew S: 7 articles (07/2022 - 06/2014)
10.	Schnaar, Ronald L: 7 articles (01/2022 - 01/2014)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "This updated study suggested the expression of Siglec-15 is significantly associated with poor outcomes in human solid tumors, but further studies are needed to determine the prognostic value of Siglec-15 in solid tumors." 11/01/2021 - "Mechanistic studies have shown that hypersialylation on cancer cells can engage inhibitory Siglecs on the surface of immune cells and induce immunosuppression. " 01/01/2021 - "Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. " 01/01/2020 - "In the present study, we hypothesized that it is possible to use genetically engineered T-cells expressing siglec-based CARs, enabling them to recognize and eliminate tumor cells, in a non-histocompatibility complex molecule restricted way. " 01/01/2020 - "Recent studies have shown that tumor cells can exploit sialoglycan-Siglec interactions to modulate immune cell function, contributing to an immunosuppressive tumor microenvironment (TME). "
2.	Inflammation (Inflammations) 11/15/2020 - "Histological analyses of joint destruction provided evidence for a significant reduction in bone erosion area and osteoclast numbers in Siglec-15-/- mice, whereas the inflammation area and cartilage destruction was comparable to wild-type mice. " 01/01/2019 - "Our study reveals that Siglec-G orchestrates TLR-induced inflammation, which outlines that blocking Siglec-G or activating Src may be a promising strategy for both acute and chronic inflammatory diseases." 10/01/2011 - "Studies in this pre-clinical model of EoE suggest that Siglec-F (and its human paralog Siglec-8) may be novel therapeutic targets to reduce eosinophilic inflammation in EoE." 01/01/2023 - "When considering allergic inflammation, human eosinophils and mast cells express overlapping but distinct patterns of Siglecs. " 02/16/2021 - "Furthermore, administration of antibody to Siglec-E, mouse functional ortholog of Siglec-9, restrained recruitment and activation of neutrophils in mouse models of airway inflammation in vivo. "
3.	Autoimmune Diseases (Autoimmune Disease) 01/01/2023 - "In this review, we highlight potential of Siglecs in suppressing immune responses causing autoimmune diseases. " 01/01/2023 - "Impact of Siglecs on autoimmune diseases." 01/01/2021 - "With both types of viruses we did not observe induction of autoimmune disease in Siglec-H-deficient mice. " 01/01/2017 - "Larger comparisons of mixed ethnicity might, however, reveal an important role for Siglecs in the pathogenesis of autoimmune disease." 07/01/2015 - "Although higher B1 cell numbers are discussed to be associated with autoimmunity, loss of Siglec-G does not result in autoimmune disease in BALB/c mice. "
4.	Asthma (Bronchial Asthma) 10/01/2020 - "Developmental eosinophils peaked during P10-14 and exhibited Siglec-Fmed/highCD11c-/low phenotypes, similar to allergic asthma models. " 02/01/2016 - "Phenotypic plasticity and targeting of Siglec-F(high) CD11c(low) eosinophils to the airway in a murine model of asthma." 05/01/2014 - "Mfsd10 as well as Siglec-F could be an effective target to treat eosinophil-related disorders including bronchial asthma." 01/01/2014 - "We aimed to determine whether post-sensitization with anti-IL-33/anti-Siglec-F treatments exhibited more potent effects compared to individual treatments in a murine allergic asthma model. " 01/01/2014 - "We show that monitoring the occurrence of eosinophils, a prominent feature of allergic asthma, by means of a NIRF-labeled antibody directed against Siglec-F is a novel and powerful non-invasive optical imaging approach to assess EAAD and therapeutic response in mice over time."
5.	Eosinophilia 01/01/2022 - "Using a competitive mixed bone marrow chimera approach with wild-type and Siglec-F-deficient eosinophils, we observed no evidence for Siglec-F-regulated inhibition of Aspergillus fumigatus-elicited lung eosinophilia. " 01/01/2019 - "Finally, treatment of humanized mice with anti-Siglec antibody led to robust depletion of IL-5-induced eosinophilia in vivo. " 07/01/2014 - "These data demonstrate that siglec-F-dependent regulation of eosinophilia is subtle and depends critically on the model used. " 07/01/2014 - "In models of allergic eosinophilic airway inflammation, siglec-F was shown previously to be important for negatively regulating eosinophilia. " 10/01/2011 - "Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis."

Related Drugs and Biologics

1.	N-Acetylneuraminic Acid (Sialic Acid)
2.	Ligands
3.	Sialic Acid Binding Immunoglobulin-like Lectins
4.	Lectins
5.	Polysaccharides (Glycans)
6.	Galectins (Galectin)
7.	Selectins
8.	C-Type Lectins (C-Type Lectin)
9.	Tacrolimus (Prograf)
10.	Anticoagulants

Related Therapies and Procedures

1.	Immunotherapy
2.	Transplantation
3.	Therapeutics
4.	Immunomodulation
5.	Nanospheres